0001493152-22-033252.txt : 20221122 0001493152-22-033252.hdr.sgml : 20221122 20221122091017 ACCESSION NUMBER: 0001493152-22-033252 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20221116 ITEM INFORMATION: Material Modifications to Rights of Security Holders ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20221122 DATE AS OF CHANGE: 20221122 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Qualigen Therapeutics, Inc. CENTRAL INDEX KEY: 0001460702 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 263474527 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37428 FILM NUMBER: 221407872 BUSINESS ADDRESS: STREET 1: 2042 CORTE DEL NOGAL STREET 2: CARLSBAD CITY: CALIFORNIA STATE: CA ZIP: 92011 BUSINESS PHONE: (760) 918-9165 MAIL ADDRESS: STREET 1: 2042 CORTE DEL NOGAL STREET 2: CARLSBAD CITY: CALIFORNIA STATE: CA ZIP: 92011 FORMER COMPANY: FORMER CONFORMED NAME: RITTER PHARMACEUTICALS INC DATE OF NAME CHANGE: 20090402 8-K 1 form8-k.htm
0001460702 false --12-31 0001460702 2022-11-16 2022-11-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 16, 2022

 

Qualigen Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-37428   26-3474527

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

 

2042 Corte Del Nogal, Carlsbad, California 92011

(Address of principal executive offices) (Zip Code)

 

(760) 918-9165

(Registrant’s telephone number, including area code)

 

n/a

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol   Name of each exchange on which registered
Common Stock, par value $.001 per share   QLGN   The Nasdaq Capital Market of The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act (§230.405 of this chapter) or Rule 12b-2 of the Exchange Act (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

 

 

 

 
 

 

Item 3.03. Material Modification to Rights of Security Holders.

 

To the extent required by Item 3.03 of Form 8-K, the information regarding the Reverse Stock Split (as defined below) contained in Item 5.03 of this Current Report on Form 8-K is incorporated by reference herein.

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Amendment No. 2 to 2020 Stock Incentive Plan

 

On November 16, 2022, the board of directors of Qualigen Therapeutics, Inc. (the “Company”) approved an amendment (the “Plan Amendment”) to the 2020 Stock Incentive Plan of Qualigen Therapeutics, Inc. (the “2020 Plan”), which will become effective November 23, 2022 at 12:01 a.m, Eastern Time in connection with the Reverse Stock Split (as defined below). The Plan Amendment ratably adjusted the aggregate number of shares of common stock, par value $0.001 per share (the “Common Stock”), issuable under the 2020 Plan to reflect the Reverse Stock Split. Equity and equity-based awards outstanding under the 2020 Plan will also be ratably adjusted to reflect the Reverse Stock Split.

 

The description of the Plan Amendment contained in this Item 5.02 is qualified in its entirety by reference to the full text of the Plan Amendment, which is filed as Exhibit 10.1 hereto and is incorporated by reference herein.

 

Amendment No. 1 to 2022 Employee Stock Purchase Plan

 

On November 16, 2022, the board of directors of the Company approved an amendment (the “ESPP Amendment”) to the 2022 Employee Stock Purchase Plan of Qualigen Therapeutics, Inc. (the “2022 ESPP”), which will become effective November 23, 2022 at 12:01 a.m, Eastern Time in connection with the Reverse Stock Split (as defined below). The ESPP Amendment ratably adjusted the aggregate number of shares of Common Stock issuable under the 2022 ESPP to reflect the Reverse Stock Split.

 

The description of the ESPP Amendment contained in this Item 5.02 is qualified in its entirety by reference to the full text of the ESPP Amendment, which is filed as Exhibit 10.2 hereto and is incorporated by reference herein.

 

Item 5.03. Amendment to Articles of Incorporation or Bylaws; Change in Fiscal Year.

 

On November 21, 2022, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation, as amended (the “Amendment”) with the Secretary of State of the State of Delaware to effect a 1-for-10 reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding Common Stock, effective November 23, 2022 at 12:01 a.m., Eastern Time (the “Effective Time”).

 

The Reverse Stock Split was approved by the Company’s stockholders at the Company’s reconvened annual meeting of stockholders held on October 28, 2022, at a ratio of not less than 1-for-5 and not greater than 1-for-10, with the exact ratio, if approved and effected at all, to be set within that range at the discretion of the board of directors. On November 22, 2022, the Company announced that its board of directors had set a ratio of 1-for-10 for the Reverse Stock Split.

 

The Amendment provides that at the Effective Time, every 10 shares of the Company’s issued and outstanding Common Stock immediately prior to the Effective Time, will automatically be reclassified, without any action on the part of the holder thereof, into one share of Common Stock. No fractional shares will be issued as a result of the Reverse Stock Split. Stockholders who otherwise would be entitled to receive a fractional share in connection with the Reverse Stock Split will receive a cash payment in lieu thereof.

 

Equiniti Trust Company is acting as exchange agent for the Reverse Stock Split and will send instructions to stockholders of record who hold stock certificates regarding the exchange of certificates for Common Stock, should they wish to do so. Stockholders who hold their shares in brokerage accounts or “street name” are not required to take any action to effect the exchange of their shares.

 

Commencing on November 23, 2022, trading of the Company’s Common Stock will continue on the Nasdaq Capital Stock Market on a reverse stock split-adjusted basis. The new CUSIP number for the Company’s Common Stock following the Reverse Stock Split is 74754R 202.

 

The foregoing description of the Amendment does not purpose to be complete and is qualified in its entirety by reference to the full text of the Amendment, which is filed as Exhibit 3.1 to this report and is incorporated by reference herein.

 

 
 

 

Item 7.01. Regulation FD Disclosure.

 

The Company announced the matters described in Item 5.03 above in a press release entitled “Qualigen Therapeutics Announces 1-for-10 Reverse Stock Split” on November 22, 2022.

 

The information in this Item 7.01 (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall the information in this Item 7.01 (including Exhibit 99.1 attached hereto) be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
     
3.1   Certificate of Amendment to the Amended and Restated Certificate of Incorporation, as amended.
     
10.1   Amendment No. 2 to the 2020 Stock Incentive Plan of Qualigen Therapeutics, Inc.
     
10.2   Amendment No. 1 to the 2022 Employee Stock Purchase Plan of Qualigen Therapeutics, Inc.
     
99.1   Press Release dated November 22, 2022, entitled “Qualigen Therapeutics Announces 1-for-10 Reverse Stock Split.”
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  QUALIGEN THERAPEUTICS, INC.
     
Date: November 22, 2022 By: /s/ Michael S. Poirier
    Michael S. Poirier, Chief Executive Officer

 

 

 

 EX-3.1 2 ex3-1.htm

 

Exhibit 3.1

 

QUALIGEN THERAPEUTICS, INC.

 

CERTIFICATE OF AMENDMENT

 

TO

 

THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION

 

Qualigen Therapeutics, Inc. (the “Corporation”), a corporation duly organized and existing under the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify that:

 

1. The name of the corporation is Qualigen Therapeutics, Inc.

 

2. This Certificate of Amendment (the “Certificate of Amendment”) amends the provisions of the Corporation’s Amended and Restated Certificate of Incorporation first filed with the Secretary of State of Delaware on September 16, 2008, as amended (the “Certificate of Incorporation”).

 

3. Article IV, Subsection A of the Certificate of Incorporation is hereby amended and restated in its entirety as follows:

 

“(A) The total number of shares of stock that the Corporation shall have authority to issue is Two Hundred Forty Million (240,000,000), consisting of Two Hundred Twenty-Five Million (225,000,000) shares of common stock, $0.001 par value per share (the “Common Stock”), and Fifteen Million (15,000,000) shares of preferred stock, $0.001 par value per share (the “Preferred Stock”).

 

Effective 12:01 A.M., Eastern Time (the “Effective Time”), on November 23, 2022 (the “Effective Date”) pursuant to the Delaware General Corporation Law and this Certificate of Amendment to the Certificate of Incorporation of the Corporation, each ten (10) shares of Common Stock issued and outstanding immediately prior to the Effective Time on the Effective Date shall, automatically and without any action on the part of the respective holders thereof, be combined and converted into one (1) share of Common Stock (the “Reverse Stock Split”). No fractional shares shall be issued in connection with the Reverse Stock Split. Stockholders who otherwise would be entitled to receive fractional shares of Common Stock shall be entitled to receive cash (without interest or deduction) from the Corporation’s transfer agent in lieu of such fractional share interests upon the submission of a transmission letter by a stockholder holding the shares in book-entry form and, where shares are held in certificated form, upon the surrender of the stockholder’s Old Certificates (as defined below), in an amount equal to the product obtained by multiplying (a) the closing price per share of the Common Stock as reported on the Nasdaq Capital Market on the Effective Date, by (b) the fraction of one share owned by the stockholder. Each certificate that immediately prior to the Effective Time on the Effective Date represented shares of Common Stock (“Old Certificates”), shall thereafter represent that number of shares of Common Stock into which the shares of Common Stock represented by the Old Certificate shall have been combined, subject to the elimination of fractional share interests as described above.”

 

4. This Certificate of Amendment was duly adopted in accordance with the provisions of Section 242 of the DGCL.

 

 

 

 

IN WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment to be signed by its Chief Executive Officer on this 21st day of November, 2022.

 

  QUALIGEN THERAPEUTICS, INC.
     
  By: /s/ Michael Poirier
  Name: Michael Poirier
  Title: Chief Executive Officer

 

 

 

 EX-10.1 3 ex10-1.htm

 

Exhibit 10.1

 

AMENDMENT NO. 2

to the

2020 STOCK INCENTIVE PLAN

of

QUALIGEN THERAPEUTICS, INC.

 

(Effective November 23, 2022)

 

This Amendment No. 2 (this “Amendment”) to the 2020 Stock Incentive Plan of Qualigen Therapeutics, Inc. (the “Company”) is hereby adopted by the Board of Directors of the Company (the “Board”), effective as of the date first referenced above.

 

WHEREAS, the 2020 Stock Incentive Plan of Qualigen Therapeutics, Inc. (the “Plan”) was adopted by the Board on behalf of the Company on April 8, 2020;

 

WHEREAS, the Plan was subsequently amended by the Company’s stockholders on August 9, 2021;

 

WHEREAS, as of the date first set forth above, the Company has effectuated a 1-for-10 reverse stock split (the “Reverse Split”) of the shares of the Company’s common stock, par value $0.001 per share (“Common Stock”);

 

WHEREAS, pursuant to Section 3.5 of the Plan, if the number of outstanding shares of Common Stock (the “Shares”) is changed by a stock dividend, extraordinary dividends or distributions (whether in cash, shares or other property, other than a regular cash dividend) recapitalization, stock split, reverse stock split, subdivision, combination, reclassification, spin-off or similar change in the capital structure of the Company without consideration, then (a) the number of Shares reserved for issuance and future grant under the Plan set forth in Section 3.1 of the Plan, (b) the exercise prices of and number of Shares subject to outstanding Options and Stock Appreciation Rights; (c) the number of Shares subject to other outstanding Awards; (d) the maximum number of shares that may be issued as incentive stock options (“ISOs”) set forth in Section 3.4 of the Plan; and (e) the number of Shares that may be granted as Awards to Non-Employee Directors as set forth in Article 10 of the Plan, will be proportionately adjusted, subject to any required action by the Board or the stockholders of the Company and in compliance with applicable securities laws, provided that fractions of a Share will not be issued.; and

 

WHEREAS, the Board wishes to amend the Plan to make certain adjustments contemplated by Section 3.5 of the Plan to reflect the Reverse Split.

 

NOW, THEREFORE, BE IT RESOLVED,

 

1. Section 3.1 of the Plan is hereby amended to change the total number of Shares reserved and available for grant and issuance pursuant to the Plan from 7,557,157 to 755,715.
   
2. Section 3.4 of the Plan is hereby amended to change the Shares that may be issued pursuant to the exercise of ISOs from 98,000,000 to 9,800,000.
   
3. Except as modified herein, all terms and conditions of the Plan shall remain in full force and effect.
   
4. This Amendment shall be construed and enforced in accordance with and governed by the laws of the State of Delaware, without regard to conflicts of law.
   
5. If any provision of this Amendment is or becomes invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not be affected thereby.

 

 

 

 

 EX-10.2 4 ex10-2.htm

 

Exhibit 10.2

 

AMENDMENT NO. 1

to the

2022 EMPLOYEE STOCK PURCHASE PLAN

of

QUALIGEN THERAPEUTICS, INC.

 

(Effective November 23, 2022)

 

This Amendment No. 1 (this “Amendment”) to the 2022 Employee Stock Purchase Plan of Qualigen Therapeutics, Inc. (the “Company”) is hereby adopted by the Board of Directors of the Company (the “Board”), effective as of the date first referenced above.

 

WHEREAS, the 2022 Employee Stock Purchase Plan of Qualigen Therapeutics, Inc. (the “ESPP”) was adopted by the Board on behalf of the Company on July 8, 2022 and approved by the Company’s stockholders on August 25, 2022;

 

WHEREAS, as of the date first set forth above, the Company has effectuated a 1-for-10 reverse stock split (the “Reverse Split”) of the shares of the Company’s common stock, par value $0.001 per share (“Common Stock”);

 

WHEREAS, pursuant to Section 8.1 of the ESPP, in the event of any stock dividend, stock split, combination or reclassification of shares, merger, consolidation, spin-off, recapitalization, distribution of Company assets to stockholders (other than normal cash dividends), or any other similar corporate event affecting the Common Stock, the Administrator of the ESPP may make such proportionate adjustments, if any, as the Administrator in its sole discretion may deem appropriate to reflect such change with respect to (a) the aggregate number and type of shares of Common Stock (“Shares”) (or other securities or property) that may be issued under the Plan (including, but not limited to, adjustments to the limitations in Section 3.1 of the ESPP), (b) the purchase price with respect to any outstanding rights, and (c) the class(es) and number of shares of Common Stock and price per share of Common Stock subject to outstanding rights; and

 

WHEREAS, the Board wishes to amend the ESPP to make certain adjustments contemplated by Section 8.1 of the ESPP to reflect the Reverse Split.

 

NOW, THEREFORE, BE IT RESOLVED,

 

1. Section 3.1 of the ESPP is hereby amended to change the aggregate number of Shares that may be issued pursuant to rights granted under the Plan from 1,000,000 to 100,000; provided, however, that commencing on January 1, 2024 and on each January 1 thereafter during the term of the ESPP, the number of Shares reserved and available for issuance under the ESPP shall be increased by the lesser of (a) 1.0% of the number of outstanding Shares as of December 31 of the preceding calendar year or (b) such lesser number of Shares as determined by the Administrator. Section 3.1 is also amended to change the maximum aggregate number of Shares that may be issued or transferred pursuant to rights granted under the ESPP from 1,200,000 to 120,000.
   
2. Except as modified herein, all terms and conditions of the Plan shall remain in full force and effect.
   
3. This Amendment shall be construed and enforced in accordance with and governed by the laws of the State of Delaware, without regard to conflicts of law.
   
4. If any provision of this Amendment is or becomes invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not be affected thereby.

 

 

 

 

 EX-99.1 5 ex99-1.htm

 

Exhibit 99.1

 

 

Qualigen Therapeutics, Inc. Announces 1-for-10 Reverse Stock Split

 

Action to comply with continued listing requirements for Nasdaq Capital Market

 

CARLSBAD, Calif., November 22, 2022 — Qualigen Therapeutics, Inc. (Nasdaq: QLGN Qualigen Therapeutics, Inc.), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces that its board of directors (the “Board”) has approved a 1-for-10 reverse stock split of the Company’s common stock. The reverse stock split will become effective at 12:01 am ET on November 23, 2022 and begin trading on a split-adjusted basis at the market open on November 23, 2022 with the new CUSIP number 74754R 202.

 

The Company is implementing the reverse stock split to enable it to regain compliance with the Nasdaq $1.00 minimum bid price requirement.

 

The reverse stock split was approved by the Company’s stockholders at the Company’s reconvened 2022 Annual Meeting, held on October 28, 2022, at a ratio of not less than 1-for-5 and not greater than 1-for-10, with the exact ratio, if approved and effected at all, to be set within that range at the discretion of the Board.

 

As a result of the reverse stock split, every 10 shares of the Company’s common stock issued and outstanding will be automatically reclassified into one share of common stock. No fractional shares will be issued in connection with the reverse split. Stockholders will be entitled to a cash payment in lieu of any fractional shares.

 

All outstanding stock options, warrants, and equity incentive plans will be proportionately adjusted. The exercise prices of outstanding stock options and warrants, and shares reserved under the Company’s equity incentive plans will be adjusted in accordance with their respective terms. The reverse stock split will affect all stockholders uniformly and will not affect any stockholder’s ownership percentage of Company shares, with the exception of those stockholders receiving cash in lieu of fractional shares.

 

Equiniti Trust Company (“Equiniti”) is acting as the exchange agent and transfer agent for the reverse stock split. Equiniti will provide instructions to stockholders with physical certificates regarding the process for exchanging their certificates for split-adjusted shares into “book-entry form” and receiving payment for fractional shares, if any. Those stockholders who hold common stock in “street name” will receive instructions from their brokers.

 

“The reverse stock split is of paramount importance to Qualigen as it is the means by which our stock remains on the Nasdaq Capital Market and furthers our ability to meet our financial needs to execute on our various development programs,” commented Michael Poirier, Qualigen’s Chairman and CEO. “We are grateful to our stockholders who recognize this value, and who support our innovative therapeutic programs for rare cancers, including our lead program QN-302, targeted to become clinical stage in 2023. We look forward to the opportunity to achieve more important milestones and to report back to our stockholders as we make progress.”

 

 
 

 

About Qualigen Therapeutics, Inc.

 

Qualigen Therapeutics, Inc. is a diversified life sciences company focused on developing treatments for adult and pediatric cancer, as well as maintaining and expanding its core FDA-cleared FastPack ® System, which has been used successfully in diagnostics for over 20 years. Our investigational QN-302 compound is a small molecule selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells; such binding could, by stabilizing the G4s against “unwinding,” help inhibit cancer cell proliferation. The investigational compounds within Qualigen’s family of RAS oncogene protein-protein interaction inhibitor small molecules are believed to inhibit or block the binding of mutated RAS genes’ proteins to their effector proteins, thereby leaving the proteins from the mutated RAS unable to cause further harm. In theory, such mechanism of action may be effective in the treatment of about one quarter of all cancers, including certain forms of pancreatic, colorectal, and lung cancers. Our investigational QN-247 compound inhibits nucleolin, a key multi-functional regulatory protein that is overexpressed in cancer cells; QN-247 may thereby be able to inhibit the cells’ proliferation. QN-247 has shown promise in preclinical studies for the treatment of acute myeloid leukemia (AML). In addition to its oncology drug pipeline, Qualigen has an established diagnostics business which manufactures and distributes proprietary and highly accurate rapid blood testing systems to physician offices and small hospitals for the management of prostate cancer and other diseases and health conditions.

 

For more information about Qualigen Therapeutics, Inc., please visit www.qualigeninc.com.

 

Contact:

Jules Abraham

JQA Partners, Inc.

917-885-7378

jabraham@jqapartners.com

Source: Qualigen Therapeutics, Inc.

 

 

 GRAPHIC 6 ex99-1_001.jpg begin 644 ex99-1_001.jpg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qlgn-20221116.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 8 qlgn-20221116_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 9 qlgn-20221116_pre.xml XBRL PRESENTATION FILE XML 10 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover
Nov. 16, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 16, 2022
Current Fiscal Year End Date --12-31
Entity File Number 001-37428
Entity Registrant Name Qualigen Therapeutics, Inc.
Entity Central Index Key 0001460702
Entity Tax Identification Number 26-3474527
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 2042 Corte Del Nogal
Entity Address, City or Town Carlsbad
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92011
City Area Code (760)
Local Phone Number 918-9165
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $.001 per share
Trading Symbol QLGN
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 11 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001460702 2022-11-16 2022-11-16 iso4217:USD shares iso4217:USD shares 0001460702 false --12-31 8-K 2022-11-16 Qualigen Therapeutics, Inc. DE 001-37428 26-3474527 2042 Corte Del Nogal Carlsbad CA 92011 (760) 918-9165 false false false false Common Stock, par value $.001 per share QLGN NASDAQ false EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 13 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://qualigeninc.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm ex10-1.htm ex10-2.htm ex3-1.htm ex99-1.htm qlgn-20221116.xsd qlgn-20221116_lab.xml qlgn-20221116_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "qlgn-20221116_lab.xml" ] }, "presentationLink": { "local": [ "qlgn-20221116_pre.xml" ] }, "schema": { "local": [ "qlgn-20221116.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "QLGN", "nsuri": "http://qualigeninc.com/20221116", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2022-11-16to2022-11-16", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://qualigeninc.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2022-11-16to2022-11-16", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://qualigeninc.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://qualigeninc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://qualigeninc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://qualigeninc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://qualigeninc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://qualigeninc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://qualigeninc.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://qualigeninc.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://qualigeninc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://qualigeninc.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://qualigeninc.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://qualigeninc.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://qualigeninc.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://qualigeninc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://qualigeninc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://qualigeninc.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://qualigeninc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://qualigeninc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://qualigeninc.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://qualigeninc.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://qualigeninc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://qualigeninc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://qualigeninc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://qualigeninc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://qualigeninc.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://qualigeninc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://qualigeninc.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://qualigeninc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://qualigeninc.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://qualigeninc.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://qualigeninc.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://qualigeninc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://qualigeninc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://qualigeninc.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://qualigeninc.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://qualigeninc.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://qualigeninc.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://qualigeninc.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://qualigeninc.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://qualigeninc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://qualigeninc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://qualigeninc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://qualigeninc.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://qualigeninc.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://qualigeninc.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://qualigeninc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://qualigeninc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://qualigeninc.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://qualigeninc.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://qualigeninc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://qualigeninc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://qualigeninc.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://qualigeninc.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://qualigeninc.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://qualigeninc.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://qualigeninc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://qualigeninc.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://qualigeninc.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 18 0001493152-22-033252-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-22-033252-xbrl.zip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end